Stock Price Quote

NEULAND LABORATORIES LTD.

NSE : NEULANDLABBSE : 524558ISIN CODE : INE794A01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE3566.55-94.05 (-2.57 %)
PREV CLOSE ( ) 3660.60
OPEN PRICE ( ) 3660.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 2125
TODAY'S LOW / HIGH ( )3545.00 3739.40
52 WK LOW / HIGH ( )1230.25 4338
NSE3574.45-90.45 (-2.47 %)
PREV CLOSE( ) 3664.90
OPEN PRICE ( ) 3748.65
BID PRICE (QTY) 3574.45 (24)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 38657
TODAY'S LOW / HIGH( ) 3541.00 3748.65
52 WK LOW / HIGH ( )1221 4340
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 07-01 1984
Management Info
Davuluri Rama Mohan Rao - Chairman Davuluri Saharsh Rao - Managing Director
Registered Office

Address 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee Hills,
Hyderabad,
Telangana-500033

Phone 040-67611600 / 67611700

Email neuland@neulandlabs.com

Website www.neulandlabs.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

20Jun Neuland Laboratories informs about new
Pursuant to Regulation 47 of the Securities and Exchange Board of India..
07Jun Neuland Laboratories informs about new
Neuland Laboratories has informed that it enclosed a copy of the Notice..
29May Neuland Laboratories informs about ana
Neuland Laboratories has informed that the Company’s management will be..
27May USFDA completes inspection at Unit 3 m
United States Food and Drug Administration (USFDA) has completed inspect..
04May Neuland Laboratories submits analyst m
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Re..

Financials

in Millions
QTR Jun 23 ANNUAL 23
Net Profit622.241631.19
Gross Profit 835.04 2152.13
Operating Profit 993.042810.56
Net Sales 3629.9411911.98

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Dr. Reddy's Lab (BSE)
peergroup  5671.65 (1.08%)
M.Cap ( in Cr)94594.48
Mankind Pharma (BSE)
peergroup  1740.15 (1.87%)
M.Cap ( in Cr)69708.40
TTK Healthcare (BSE)
peergroup  1175.95 (1.79%)
M.Cap ( in Cr)1661.66
Ajanta Pharma (BSE)
peergroup  1720.55 (1.15%)
M.Cap ( in Cr)21664.42
RPG Life Sciences (BSE)
peergroup  1333.50 (1.40%)
M.Cap ( in Cr)2205.48

Shareholding Pattern

NON-INSTITUTION 36.62%
PROMOTERS 36.03%
MUTUAL FUNDS/UTI 1.57%
GOVERNMENT 0.4%
FI/BANKS/INSURANCE 0%
FII 0%

About Neuland Laboratories Ltd.

Neuland Laboratories Ltd. was incorporated in the year 1984. Its today's share price is 3566.55. Its current market capitalisation stands at Rs 4575.84 Cr. In the latest quarter, company has reported Gross Sales of Rs. 11911.98 Cr and Total Income of Rs.12009.46 Cr. The company's management includes Prasad Raghava Menon, Homi Rustam Khusrokhan, Nirmala Murthy, Bharati Rao, Christopher M Cimarusti, Parampally Vasudeva Maiya, Humayun Dhanrajgir, Davuluri Saharsh Rao, Davuluri Sucheth Rao, Davuluri Rama Mohan Rao, Sarada Bhamidipati.

It is listed on the BSE with a BSE Code of 524558 , NSE with an NSE Symbol of NEULANDLAB and ISIN of INE794A01010. It's Registered office is at 11th Floor (5th Office Level),Phoenix I V Y Building, Plot No.573 A- I I I,Road No. 82, Jubilee HillsHyderabad-500033, Telangana. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are KS Aiyar & Co, MSKA & Associates, Walker Chandik & Co LLP, Walker Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.